Why the study?
Machine learning offers potential to analyze abundant healthcare data for personalized cardiovascular prevention, but its clinical strengths must be balanced with risks to privacy, safety, equity, and interpretability.
Machine learning and digital health technologies have the potential to generate personalized risk assessments and promote guideline-directed medical management in cardiovascular disease prevention.
Answers are grounded in this paper and cite their sources.
May inform personalized CVD risk assessment; leaves open whether machine learning improves outcomes in prospective trials.
Machine learning (ML) refers to computational algorithms that iteratively improve their ability to recognize patterns in data. The digitization of our healthcare infrastructure is generating an abundance of data from electronic health records, imaging, wearables, and sensors that can be analyzed by ML algorithms to generate personalized risk assessments and promote guideline-directed medical management. ML's strength in generating insights from complex medical data to guide clinical decisions must be balanced with the potential to adversely affect patient privacy, safety, health equity, and clinical interpretability. This review provides a primer on key advances in ML for cardiovascular disease prevention and how they may impact clinical practice.
No takes yet. Share an insight, caveat, or question.
Javaid et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: